Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: Sir Auric Goldfinger who wrote (8164)	8/27/2001 10:20:18 AM
From: StockDung	Read Replies (2) \| Respond to of 19428

HOW ABOUT THIS SCAM IN THE MAKING? MOVE OVER JONATHAN LABED. WILL LET YOU KNOW WHAT IT SAYS IN 24 HOURS. LOL I GOT ON THE SUCKERS LIST BY SIGNING UP VIA ONE OF THOSE NEWSLETTER THAT SPAM RAGINGBULL. THE EMAIL SAID I PAID FOR IT. MOST WILL PAY BUT NOT FOR THIS NEWSLETTER. Subj: In 24 Hours I Will Make You Rich Date: 8/27/01 3:09:09 AM Eastern Daylight Time From: ScottFraser@utarget.sparklist.com (Scott Fraser) Reply-to: Editor@ScottFraser.com (Scott Fraser) To: scott_fraser@utarget.sparklist.com (Scott Fraser) In exactly 24 hours I will send you a confidential email containing the name of a stock which I expect to increase more than 117% within the next 90 days. Normally I only reveal such secrets to my paid subscribers - people who pay me more than one thousand dollars per year. But here is why I am telling you. I want you to promise you will use some of your profits to become one of my paid subscribers. I think this is an equitable trade. I know some of you have questions. Since there are over 85,471 of you, I cannot answer all your email personally. So I have prepared the following FAQ. Q. Why won't you reveal the name of the stock for 24 hours? Major news is about to be released on the company - a fact I have learned from trusted sources. I must keep it confidential until then for regulatory reasons Q. Why do you predict a 117% increase in 90 days? I make stock predictions based on a proprietary technique known as "situational analysis". Many of the world's wealthiest families are my personal clients. I have helped create over 1,170 multi-millionaires Q. What does the company do? I cannot reveal the name, but I can tell you: It is a leader in the single largest industry in the world It trades at a FRACTION of the valutation of its peers Virtually NO ONE on Wall Street has heard of it...yet It is a company that makes money in ALL economic cycles Q. How can I buy the stock? In 24 hours I will tell you the name of the company and the stock symbol. You can place your buy orders through your broker or online brokerage account Q. What are some other stocks you have recommended? We bought Pennaco when it was at $2.50 ...17 months later we sold at $19 - a nice 660% gain Later we bought Atlas Pipeline at $12 ...11 months later we sold it at $40 We also bought Ultra Petroleum at $0.90 ...and sold it 10 months later for $9.15 In fact over 87% of my stock recommendations to my elite clientelle have increased on average 135% in the past 28 months. Q. Why are you telling me about this? A. I want you to promise me that you will take $1,000 out of the profits you make on this stock, and purchase a subscription to my elite investment alert service Remember...in 24 hours I will send you an email that could make you VERY, VERY RICH. Watch for it...Expect it...Get ready for it And when you receive it, buy the stock... And get ready to make a fortune. Sincerely on the Contrary, Scott S. Fraser Editor, The Natural Contrarian Best-Selling Author Award-Winning Investment Editor 2-Time Winner of the McPartland-Shepherd Award for Investment Excellence ON24 Analyst --- You are currently subscribed to scott_fraser as: XXXXXXXXXXXXX To unsubscribe send a blank email to leave-scott_fraser-450235A@utarget.sparklist.com In exactly 24 hours I will send you a confidential email containing the name of a stock which I expect to increase morethan 117% within the next 90 days. Normally I only reveal suchsecrets to my paid subscribers... people who pay me more than one thousand dollars per year. But here is why I am telling you. I want you topromise you will use some of your profits to become one of my paid subscribers. I think this is an equitable trade. I know some of you have questions. Since there are 85,471 of you I cannot answer all your email personally. So Ihave prepared the following FAQ. Q. Why won't you revealthe name of the stock for 24 hours? Major news is about to bereleased on the company... a fact I have learned from trustedsources.I must keep it confidential until then for regulatory reasons Q. Why do you predict a 117% increase in 90 days? I make stock predictions based on a proprietary techniqueknown as "situational analysis". Many of the world's wealthiest families are my personal clients. I have helped create over 1,170 multi-millionaires Q. What does thecompany do? I cannot reveal the name, but I can tell you:<UL> <LI>It is a leader in the single largest industry in the world <LI>It trades at a FRACTION of the valuation of its peers <LI>Virtually NO ONE on Wall Street has heard of it...yet <LI>It is a company that makes money in ALL economic cycles </LI></UL>Q. How can I buy the stock? In 24 hours I will tellyou the name of the company and the stock symbol. You can place your buyorders through your broker or online brokerage account Q. Whatare some other stocks you have recommended? We bought Pennaco whenit was at $2.50 ...17 months later we sold at $19 - a nice660% gain Later we bought Atlas Pipeline at $12 ...11months later we sold at $40 We also bought Ultra Petroleum at$0.90 ...and sold it 10 months later for $9.15 Infact over 87% of my stock recommendations to my elite clientelle haveincreased on average 135% in the past 28 months. Q. Why areyou telling me about this? I want you to promise me that you willtake $1,000 out of the profits you make on this stock, and purchase a subscription to my elite investment alert service Remember...in 24 hours I will send you an email that could make you VERY, VERY RICH. Watch for it...Expectit...Get ready for it And when you receive it, buy the stock... Andget ready to make a fortune. Sincerely on the Contrary, Scott S. Fraser Editor, The Natural Contrarian Best-Selling Author Award-Winning Investment Editor 2-TimeWinner of the McPartland Shepherd Award for Investment Excellence ON24Analyst

To: Sir Auric Goldfinger who wrote (8164)	9/28/2001 12:21:11 PM
From: RockyBalboa	Read Replies (2) \| Respond to of 19428

RVP - $7.14 Press Release SOURCE: Investrend Communications, Inc. Investrend Announces Investment Opinion: Retractable Technologies Strong Buy and $12.60 Target Initiated by Investrend Research Analyst Sherry Grisewood, CFA NEW YORK--(BUSINESS WIRE)--Sept. 24, 2001--Investrend Research (http://www.investrend.com) analyst Sherry Grisewood, CFA, has initiated coverage of Retractable Technologies, Inc. (AMEX:RVP - news), with a Strong Buy recommendation and one year price target of $12.60. The full report has been initially posted at investrend.tripod.com. According to Grisewood, ``Retractable Technologies Inc.'s (Retractable's) singular focus is to bring increased safety to the healthcare industry by designing, developing, manufacturing and marketing patented, cost effective and convenient-to-use safe engineered sharps devices. The Centers for Disease Control and Prevention reports that between 800,000 and 1 million accidental needlesticks occur annually in the U.S., with over 65% likely to go unreported. Accidental needlesticks are the primary source of hepatitis, HIV and other infectious disease contamination for healthcare workers. There are more than 20 bloodborne pathogens that are transmittable by contaminated needlesticks. Over 6.6 billion syringes are used each year in the United States, about 1/4 of the estimated 24 billion unit consumption worldwide. ``Retractable addresses this significant healthcare problem with its patented VanishPoint safety syringes and devices. The ECRI, formerly known as the Emergency Care Research Institute, gave Retractable's VanishPoint syringe and tube holder its highest possible rating in 1999. Retractable's VanishPoint syringes incorporates a patented needle retraction system that not only prevents reuse, but also completely protects the practitioner from accidental needle sticks by fully retracting the needle before the syringe is removed from the patient. Although many patents have been filed and issued, and a variety of safety syringes developed in the research labs, we believe Retractable is the only pure-play company commercially selling fully retractable safety syringes in quantity and generating meaningful revenue from these sales. We are initiating a strong buy opinion on Retractable based upon recent federal legislation and mandates driving market expansion for safety engineered sharps devices and Retractable's shares being substantially undervalued relative to its competitors.'' Sherry Grisewood, CFA, has had extensive experience as a sell-side analyst, and has worked for such firms as DLJ and EF Hutton. She has over 16 years experience as an independent special situations and small cap analyst, and has written a cash and futures market commentary since 1982. She has performed extensive analysis for investment banking projects and currently has her own practice working on securities analysis. Grisewood holds a B.S. degree with Highest Honors from Ramapo College of New Jersey, is a member of NYSSA, and is one of more than 30 professional analysts qualified into the Investrend Independent Research program since its inception in 1996. Investrend Research has been a leading independent, professional fee-based institutional publishing and distribution program since 1996. Fee-based research has recently been championed by Congress and media such as the New York Times as a preferable alternative to research tied to investment banking. Anyone, including a company, investor relations practitioner, financial institution or interested private investor, may enroll a company for analyst coverage. Analysts are paid in advance for initial reports to eliminate pecuniary interests, and are contractually responsible only to the public, following AIMR standards and ethics. To further eliminate conflicts, neither the analysts, Investrend nor any employees may own or trade in the equities of companies for which reports have been initiated. Three-year enrollment fees are $21,300 for the first year, $19,500 for year 2 and $17,200 for year 3. Please read the disclaimers and coverage guidelines at investrend.com before investing. biz.yahoo.com